BR112015019564A2 - tratamento de esclerose múltipla com laquinimod - Google Patents

tratamento de esclerose múltipla com laquinimod

Info

Publication number
BR112015019564A2
BR112015019564A2 BR112015019564A BR112015019564A BR112015019564A2 BR 112015019564 A2 BR112015019564 A2 BR 112015019564A2 BR 112015019564 A BR112015019564 A BR 112015019564A BR 112015019564 A BR112015019564 A BR 112015019564A BR 112015019564 A2 BR112015019564 A2 BR 112015019564A2
Authority
BR
Brazil
Prior art keywords
laquinimod
multiple sclerosis
human subject
treatment
sclerosis treatment
Prior art date
Application number
BR112015019564A
Other languages
English (en)
Portuguese (pt)
Inventor
Bar-Zohar Dan
Sorani Ella
Hayardeny Liat
Tarcic Nora
Gorfine Tali
Knappertz Volker
Gilgun Sherki Yossi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015019564(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112015019564A2 publication Critical patent/BR112015019564A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
BR112015019564A 2013-02-15 2014-02-13 tratamento de esclerose múltipla com laquinimod BR112015019564A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US201361911106P 2013-12-03 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
BR112015019564A2 true BR112015019564A2 (pt) 2017-07-18

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019564A BR112015019564A2 (pt) 2013-02-15 2014-02-13 tratamento de esclerose múltipla com laquinimod

Country Status (18)

Country Link
US (2) US20140235670A1 (enExample)
EP (1) EP2956137A4 (enExample)
JP (1) JP2016510343A (enExample)
KR (1) KR20150119227A (enExample)
CN (1) CN105163737A (enExample)
AU (1) AU2014216199A1 (enExample)
BR (1) BR112015019564A2 (enExample)
CA (1) CA2900503A1 (enExample)
CL (1) CL2015002181A1 (enExample)
EA (1) EA201591507A1 (enExample)
HK (2) HK1218251A1 (enExample)
IL (1) IL240014A0 (enExample)
MX (1) MX2015010296A (enExample)
PE (1) PE20151526A1 (enExample)
SG (1) SG11201505818WA (enExample)
TW (1) TW201442709A (enExample)
UY (1) UY35328A (enExample)
WO (1) WO2014127139A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
JP2017514824A (ja) * 2014-04-29 2017-06-08 テバ ファーマシューティカル インダストリーズ リミティド 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
CN107072988A (zh) * 2014-10-16 2017-08-18 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SMT202500136T1 (it) 2016-08-31 2025-05-12 Mapi Pharma Ltd Sistemi a deposito comprendenti glatiramer acetato
US11167003B2 (en) * 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
NZ573846A (en) * 2006-06-12 2012-01-12 Teva Pharma Stable laquinimod preparations
DK2187882T3 (da) * 2007-07-11 2013-04-08 Medicinova Inc Behandling af progressiv neurodegenerativ sygdom med ibudilast
TW201438738A (zh) * 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
CN102395275A (zh) * 2008-12-11 2012-03-28 拜欧维斯塔公司 用四环吡嗪并吲哚治疗多发性硬化症的方法
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
MX2013006464A (es) * 2010-12-07 2013-07-29 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.
WO2013016686A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
HK1218865A1 (zh) * 2012-10-12 2017-03-17 Teva Pharmaceutical Industries Ltd. 用於降低多发性硬化症中丘脑损伤的拉喹莫德
JP2017514824A (ja) * 2014-04-29 2017-06-08 テバ ファーマシューティカル インダストリーズ リミティド 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド

Also Published As

Publication number Publication date
CA2900503A1 (en) 2014-08-21
CN105163737A (zh) 2015-12-16
KR20150119227A (ko) 2015-10-23
CL2015002181A1 (es) 2016-06-03
AU2014216199A1 (en) 2015-09-03
PE20151526A1 (es) 2015-11-20
IL240014A0 (en) 2015-09-24
US20180064702A1 (en) 2018-03-08
SG11201505818WA (en) 2015-08-28
MX2015010296A (es) 2016-05-05
HK1218251A1 (zh) 2017-02-10
US20140235670A1 (en) 2014-08-21
UY35328A (es) 2014-09-30
TW201442709A (zh) 2014-11-16
EA201591507A1 (ru) 2015-12-30
JP2016510343A (ja) 2016-04-07
WO2014127139A1 (en) 2014-08-21
EP2956137A4 (en) 2016-08-03
HK1218254A1 (zh) 2017-02-10
EP2956137A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
BR112014028017A2 (pt) composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX375706B (es) Compuestos de inhibidor de autotaxina.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
MX2019002190A (es) Uso de pridopidina para tratar distonías.
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
BR112015023463A2 (pt) uso de sedoeptulose para prevenção ou tratamento de inflamação
BR112018002763A2 (pt) método para cicatrização de ferimentos
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
BR112013023703A2 (pt) composição tópicas que compreendem diamino oxidase para o tratamento ou prevenção de doenças associadas a altos níveis de histamina que envolvem um aumento da dor
BR112016006582A2 (pt) terapia combinada laquinimod para o tratamento da esclerose múltipla
PH12020500472A1 (en) Autotaxin inhibitor compounds
AR094809A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2501 DE 11/12/2018.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI